VIVA

This channel contains news about the annual Vascular Interventional Advances (VIVA) conference. VIVA is a premier conference for new techniques and technologies to treat vascular disease. This includes the areas of peripheral artery disease (PAD), critical limb ischemia (CLI), endovascular repair and venous therapies

 

News | VIVA

November 9, 2023 — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular ...

Home November 09, 2023
Home
News | VIVA

November 2, 2023 — The latest STRIKE-PE data, presented by Penumbra, Inc. at the Vascular Interventional Advances ...

Home November 02, 2023
Home
News | VIVA

November 2, 2023 — Contego Medical Inc. announced the presentation of late-breaking clinical results from the ...

Home November 02, 2023
Home
News | VIVA

November 2, 2023 — The second round of late-breaking clinical trials results from the Vascular InterVentional Advances ...

Home November 01, 2023
Home
News | VIVA

November 3, 2022 — Medtronic, a global leader in medical technology, today announced the results of two clinical studies ...

Home November 03, 2022
Home
News | VIVA

November 2, 2022 — The second round of late-breaking clinical trial results were announced at VIVA22 on Nov. 1 in Las ...

Home November 02, 2022
Home
News | VIVA

November 2, 2022 — A number of awards of distinction were presented during The VEINS (Venous Endovascular INterventional ...

Home November 02, 2022
Home
News | VIVA

October 31, 2022 — Results from the Late-Breaking Clinical Trials session at The VEINS Conference in Las Vegas, NV, were ...

Home October 31, 2022
Home
News | Endovascular Aortic Repair

October 26, 2022 —  Thousands of people have new hope for treatment of thoracic aortic arch disease and University ...

Home October 26, 2022
Home
News | Cardiovascular Education

September 14, 2022 — Details on late-breaking clinical trials to be presented during The VEINS (Venous Endovascular INte ...

Home September 14, 2022
Home
News | Drug-Eluting Balloons

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

Home October 20, 2021
Home
Subscribe Now